Bioventus Inc. (NASDAQ:BVS) Given Consensus Rating of “Buy” by Brokerages

Shares of Bioventus Inc. (NASDAQ:BVS) have received an average rating of “Buy” from the five ratings firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $14.00.

Several equities research analysts have commented on the stock. Barrington Research boosted their price target on shares of Bioventus from $13.00 to $14.00 and gave the stock an “outperform” rating in a research report on Friday, March 6th. Craig Hallum lifted their target price on Bioventus from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Friday, March 6th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Bioventus in a report on Monday, December 29th. Cantor Fitzgerald raised Bioventus to a “strong-buy” rating in a research report on Wednesday, March 4th. Finally, CJS Securities initiated coverage on Bioventus in a research report on Friday, March 27th. They set a “market outperform” rating and a $14.00 price target on the stock.

Bioventus Price Performance

Shares of BVS opened at $8.97 on Monday. The company has a quick ratio of 1.19, a current ratio of 1.70 and a debt-to-equity ratio of 1.22. Bioventus has a twelve month low of $5.81 and a twelve month high of $9.53. The stock has a market capitalization of $745.86 million, a P/E ratio of 27.18 and a beta of 0.70. The company has a 50 day moving average of $8.60 and a 200-day moving average of $7.74.

Bioventus (NASDAQ:BVS) last announced its quarterly earnings data on Thursday, March 5th. The company reported $0.24 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $0.02. The business had revenue of $157.90 million for the quarter. Bioventus had a net margin of 4.00% and a return on equity of 28.88%. Bioventus has set its FY 2026 guidance at 0.730-0.770 EPS.

Insider Buying and Selling at Bioventus

In related news, Director Michelle Mcmurry-Heath sold 12,000 shares of the firm’s stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $8.79, for a total value of $105,480.00. Following the completion of the transaction, the director directly owned 44,997 shares of the company’s stock, valued at approximately $395,523.63. This trade represents a 21.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 33.00% of the company’s stock.

Institutional Trading of Bioventus

Several institutional investors and hedge funds have recently added to or reduced their stakes in BVS. Nantahala Capital Management LLC grew its position in shares of Bioventus by 28.0% in the 2nd quarter. Nantahala Capital Management LLC now owns 5,280,842 shares of the company’s stock valued at $34,959,000 after acquiring an additional 1,155,192 shares during the period. Essex Investment Management Co. LLC bought a new stake in shares of Bioventus in the 4th quarter valued at about $2,886,000. Kent Lake PR LLC bought a new stake in shares of Bioventus in the 2nd quarter valued at about $2,317,000. Kennedy Capital Management LLC lifted its stake in Bioventus by 219.6% in the 3rd quarter. Kennedy Capital Management LLC now owns 461,579 shares of the company’s stock valued at $3,088,000 after purchasing an additional 317,157 shares during the last quarter. Finally, Meros Investment Management LP bought a new position in Bioventus during the fourth quarter worth about $2,345,000. 62.94% of the stock is owned by institutional investors.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.